MS
ACRS icon

Maven Securities’s Aclaris Therapeutics ACRS Stock Holding History

Maven Securities’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,605
Closed -$66K – 1014
2021
Q1 		$66K Buy
+2,605
New +$50.9K ﹤0.01% 1048

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Maven Securities's ACRS Position: Q2 2021 in Review

Maven Securities sold out of Aclaris Therapeutics (ACRS) in Q2 2021, closing a stake of 2,605 shares — an estimated $66K sold.

Maven Securities first reported a position in ACRS in Q1 2021 and held it in 1 quarter. The position peaked at $66K in Q1 2021. 128 funds tracked by Wall St. Rank hold ACRS as of Q2 2021.

  • Maven Securities reported no remaining Aclaris Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Maven Securities sold 2,605 Aclaris Therapeutics shares in Q2 2021, an estimated $66K.
  • Maven Securities first reported a position in Aclaris Therapeutics in Q1 2021 and held it in 1 quarter.
  • Maven Securities's Aclaris Therapeutics position peaked at $66K in Q1 2021.
  • 128 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.